Streetbeat News

Stock Prices

AAPL

BTCUSD

TSLA

The article covers a range of topics including US politics, world politics, Israel-Hamas conflict, tech, electric vehicles, consumer, communication, and space. Key highlights include Tesla's recall of nearly 55,000 Model X, a crypto whale losing $49K in 10 minutes due to Bitcoin ETF rumors, and Biden's planned visit to Israel. Other notable mentions include Apple's resilience in the global smartphone market, Rolls-Royce's plan to cut up to 2,500 jobs, and Netflix's intensified foray into gaming.

Portfolio Pulse from Akanksha Bakshi

October 17, 2023 | 12:37 pm

ARKK

TSLA

Cathie Wood's Ark Invest sold 7,759 shares of Tesla (TSLA) on Monday, valued at $1.97 million. This comes amid Tesla's rebound ahead of its Q3 results. Despite Tesla's recent gains, the stock is still trading below its year's intra-day high of $299.29. Ark has been selling Tesla shares since mid-June, despite remaining bullish about the company's prospects. Tesla is set to report its Q3 results on Wednesday.

Portfolio Pulse from Shanthi Rexaline

October 17, 2023 | 12:37 pm

BNMV

BitNile Metaverse, Inc. (NASDAQ:BNMV) has regained compliance with the Nasdaq Voting Rights Rule. The company had violated the rule with the issuance of the Series B and Series C Preferred Stock. The company amended the Certificates of Designation for both series to remove all voting rights, thus regaining compliance.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:36 pm

GMDA

Gamida Cell Ltd (NASDAQ:GMDA) has released early data from an ongoing Phase 1 study of its natural killer (NK) cell therapy candidate GDA-201, showing encouraging anti-tumor activity in heavily pretreated patients with CD20-positive non-Hodgkin lymphoma. Preliminary results showed marked shrinkage of target lesions in five patients. No dose-limiting toxicities were reported. The company's shares are up 6.01% at $0.94 during the premarket session.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 12:34 pm

ANGH

Anghami Inc. (NASDAQ:ANGH), a leading streaming platform in the Middle East and North Africa, has received a notification from Nasdaq for not complying with the minimum Market Value of Publicly Held Shares (MVPHS) requirement. The company has until April 8, 2024, to regain compliance by maintaining a minimum market value of publicly held shares of $15,000,000 for at least 10 consecutive business days. If the company fails to regain compliance, its securities may be delisted from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:33 pm

BK

Bank of New York Mellon Corp (NYSE:BK) reported a Q3 FY23 revenue increase of 2% Y/Y to $4.37 billion, beating the consensus of $4.33 billion. Net interest revenue increased 10% Y/Y to $1.02 billion due to higher interest rates. Adjusted EPS was $1.27 (+5% Y/Y), above the consensus of $1.15. BK shares are trading higher by 0.74% at $42.15 premarket.

Portfolio Pulse from Lekha Gupta

October 17, 2023 | 12:28 pm

OLK

Trading of Olink Holding ADS shares is set to resume at 8:50 a.m. ET.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:26 pm

OLK

TMO

Thermo Fisher Scientific Inc. (TMO) has announced plans to acquire Olink Holding AB (OLK) for $26.00 per common share in cash, a 74% premium to Olink's closing price on October 16, 2023. The deal values Olink at approximately $3.1 billion. Olink's proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. The acquisition is expected to be completed by mid-2024, subject to regulatory approvals. Olink is expected to deliver over $200M of revenue in 2024 and grow mid-teens organically as part of Thermo Fisher.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:26 pm

VLRS

Barclays analyst Pablo Monsivais has maintained an Overweight rating on Controladora Vuela (NYSE:VLRS) but lowered the price target from $22 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:24 pm

CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) has expanded its commercialization leadership team ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. The company has appointed William Yoon as vice president, medical affairs and Aaditya Nanduri as vice president, business strategy and analytics. Both appointees have been granted a non-qualified inducement stock option to purchase an aggregate of 50,000 shares of Cellectar's common stock.

Portfolio Pulse from Happy Mohamed

October 17, 2023 | 12:21 pm